Editorial Board
Anup Kasi Loknath Kumar
University of Kansas · United States
Editorial leadership for Journal of Hematology and Oncology Research ISSN 2372-6601
Research interests
- Oncology Hematology Gi Oncology
Biography
1) M.D. - Bangalore Medical College and Research Institute
2) M.P.H. - University of Texas School of Public Health
3) Residency- Internal Medicine, University of Kansas Medical Center
4) Fellowship- Hem/Onc, University of Kansas Cancer Center
5) Sub Fellowship- GI Oncology, University of Kansas Cancer Center
Selected publications
- A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors 2020 cited 281×
- Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review 2020 cited 70×
- Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study 2024 cited 37×
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study Recent 2025 cited 34×
- Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice 2020 cited 28×
- Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial Recent 2025 cited 22×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JHOR for your work?
This journal is guided by Anup Kasi Loknath Kumar (University of Kansas) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.